The global prefilled syringe (PFS) market was estimated at $7.22 billion in 2022 and is forecast to grow to $16.32 billion by 2030. The use of PFSs to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Lonza has used advanced testing capabilities to assess the factors that could impact injection force and developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.